A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2
inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR)
inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best
dose of fluzoparib in combination with apatinib and to see how well these two drugs work
together in the treatment of patients with recurrent ovarian cancer or triple negative breast
cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored.
Both dose escalation and dose expansion parts are included in this study.